|
Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination Clinical research trials and Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination. Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination clinical trial. Human subjects often receive the most effective healthcare possible for their Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination  Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination
Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination
For Condition: HIV Infections
Status: Terminated
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) , Immune Response
Synopsis: The purpose of this study is to see if giving a vaccine (Remune) is effective in HIV-positive patients who are also taking anti-HIV therapy. Regular treatment of HIV-positive patients with anti-HIV drugs slows the multiplication of the HIV virus in the body. A vaccine called Remune works to stop the virus infection by "boosting" the body's immune cell defense against the HIV virus before the virus enters cells. It also blocks the virus from entering the cells. This study will see whether Remune will improve the immune cell natural defense in patients who are also taking anti-HIV drugs.
Details: During primary HIV infection, after an initial burst in viral load, the body mounts an immunologic response to viral antigens. It is thought that this initial immune response plays an important role in determining early and long-term suppression of HIV. However, limited information is available regarding the effect of early antiretroviral therapy on immune responses. Therapeutic approaches such as Remune, which augment cell-mediated immunologic responses, may prove to be beneficial in controlling the progression of HIV infection, especially when used in combination with antiretroviral therapy in early infection. Current antiviral drugs work by inhibiting the infection of new cells yet seem to suppress early cell-mediated immune responses. The question is raised as to whether immune-based therapies such as Remune may counteract the suppressive effects of antiretrovirals and slow the progression of infection. Patients receiving fully suppressive antiretroviral therapy are randomized to add either Remune or an Incomplete Freund's Adjuvant (IFA) control. Vaccinations are administered on Day 1, Week 12, and Week 24. Blood samples are collected at Day 1 and Weeks 4, 12, 16, 24, and 28. Clinical assessment includes lymphocyte proliferative response, cytotoxic T lymphocyte (CTL) memory cell activity, chemokine and cytokine measurements, CD4 count, and viral load. Delayed-type hypersensitivity (DTH) skin tests are performed at Day 1 and Week 28. HIV-1 specific immunogenicity is coordinated with the response to antiretroviral therapy in patients.
Eligibility:
Study Type: Interventional, Treatment, Double-Blind, Safety Study
Minimum Age/Maximum Age: 16 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients may be eligible for this study if they: - Are HIV-positive and started anti-HIV drugs soon after tests showed the presence of HIV. - Have been on an anti-HIV drug combination that includes a protease inhibitor for at least 3 months but no longer than 12 months. - Have 2 consecutive viral loads of less than 50 copies/ml, at least 30 days apart, within 90 days of study entry. - Are at least 16 years old (consent of parent or guardian required if under 18 years). - Agree to practice abstinence or use effective methods of birth control during the study. Exclusion Criteria Patients will not be eligible for this study if they: - Are pregnant or breast-feeding. - Currently abuse alcohol or drugs. - Are currently being treated for some types of cancer. - Have any illness or condition that might interfere with the study or put them at risk. - Have received a vaccination 6 weeks before study entry. - Have previously received Remune. - Are taking medications that affect the immune system within 30 days of study entry.
Total Enrollment: 45
Location and Contact Information:
Overall Study Official:
EricDaar, Principal Investigator,
Joanne Santangelo
San Diego, California, 92103
United States
Additional Information:
Study ID Numbers: AIEDRP AI-05-006; 905
Study Start Date:
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006153
Other Hiv Infections Studies:
1. A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection
2. A Study of ddC in Patients with AIDS or Advanced AIDS-Related Complex (ARC) Who Have Not Had Success with Zidovudine (AZT)
3. A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients with AIDS
4. A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir
5. Curb, Alter, Lower, or Manage Stress in HIV: CALMS-HIV
Related Studies:
Other HIV Infections Clinical Trials
Other California Clinical Trials
Other San Diego Clinical Trials
Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination
|
|
|
|
|
|
|
|
